【摘要】：肺動脈高壓是以血管收縮、血管重構(gòu)、平滑肌細胞增殖和原位血栓形成等為主要特征的肺小動脈異常疾病。Selexipag是一種新型口服前列環(huán)素受體激動劑,已被證明可改善Ⅱ期臨床試驗的血液動力學,并可減少Ⅲ期臨床試驗中肺動脈高壓患者的疾病惡化情況。本文對其作用機制、藥動學、藥效學、臨床試驗、不良反應(yīng)等方面做一綜述。
[Abstract]:Pulmonary hypertension is a pulmonary arteriolar abnormality characterized by vasoconstriction, vascular remodeling, smooth muscle cell proliferation and in situ thrombosis. Selexipag is a novel oral prostacyclin receptor agonist. It has been shown to improve hemodynamics in phase II clinical trials and to reduce the deterioration of pulmonary hypertension in phase 鈪，

本文編號：2271453